PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 10 | 1 |
Article title

Use of antiviral therapy in patients with chronic hepatitis C

Content
Title variants
Languages of publication
EN
Abstracts
EN
Introduction: The presence of background HCV
infection cannot be overestimated in view of the prevalence
of chronic hepatitis C and the risk of adverse outcomes
of this disease. Purpose of this study was to evaluate
the effectiveness of the combined use of antiviral therapy
(Roferon + Vero-Ribavirin) and resort factors in patients
with chronic hepatitis C in the phase of replication.
Material and methods: We observed 48 patients with
chronic hepatitis C; the minimum level of activity of the
process defined the phase of replication. Markers of HCV
infection were determined by enzyme linked immunosorbent
assay (ELISA) (a-HCV and HCV-Ig M). HCV RNA
was determined twice by the polymerase chain reaction
(PCR). Genotyping of hepatitis C virus was performed.
Biochemical blood analysis and the study of HCV infection
markers were carried out four times. Results of therapy
were assessed immediately after the end of the resort
(spa) treatment, then at 3, 6 and 12 months after starting
treatment. At 12 months after starting treatment, all the
observed patients had persistent clinical and biochemical
remission. Elimination of the virus from the blood was
noted in 56% of the control group and 74% of patients in
the study group.
Conclusions: For patients with moderately active HCV, the
replication phase was characterized by asthenic-vegetative
syndrome (100% of patients) with severe depression (22.92%), pain (77.08%) and dyspeptic syndrome (33.33%),
moderate hypertransferaseemia (100%), slightly pronounced
cholestasis (33% of patients), and signs of mesenchymal-
inflammatory response.
Publisher
Journal
Year
Volume
10
Issue
1
Physical description
Dates
received
14 - 5 - 2014
online
20 - 3 - 2015
accepted
30 - 9 - 2014
References
  • [1] Kharchenko NV, Babak OJ. Gastroenterology. K. 2007; 720.[Harchenko N.V., Babak O.Ja., Gastroenterologіja.- K.: 2007. -720 s.] In Russian
  • [2] Degtyareva II. Clinical gastroenterology. Medical InformationAgency 2004; 616. [Degtjareva I.I. Klinicheskaja gastrojenterologija.– M.: Medicinskoe informacionnoe agentstvo, 2004.– 616 s.] In Russian
  • [3] Dragomiretskaya NV. Early resort rehabilitation and restorativetreatment in gastroenterology: Monograph. ORIDU Nadu,Odesa, 2007; 176. [Dragomireckaja N.V. Rannja kurortnareabіlіtacіja ta vіdnovljuval‘ne lіkuvannja v gastroenterologії:Monografіja. - Odesa, ORІDU NADU, 2007. - 176 s.] In Russian
  • [4] Dragomiretskaya NV. The effectiveness of health. Resort rehabilitationof patients with chronic hepatitis C. Int J Immunoreab2001; 3: 112. [Dragomireckaja N.V. Jeffektivnost‘ kurortnojreabilitacii bol‘nyh hronicheskim gepatitom S. Internationaljournal on immunoreabilitation. May 2001. – Vol. 3, 2. – P .112.] In Russian
  • [5] Dragomiretskaya NV, Malykhina TI. Izha AN. The use oflow-mineralized mineral water and cytrarginine in complextreatment of patients with chronic hepatitis C. Rus J GastroenterolHepatol Coloproctol 2005; 1: 11. [Dragomireckaja N.V.,Malyhina T.I., Izha A.N. Primenenie malomineralizovannojmineral‘noj vody i citrarginina v kompleksnom lechenii bol‘nyhhronicheskim gepatitom S. Rossijskij zhurnal gastrojenterologii,gepatologii, koloproktologii. – 2005. - # 1. – S. 11.] InRussian
  • [6] Nikitin IG. Treatment of chronic hepatitis C: yesterday,today and tomorrow. Russian Journal of Gastroenterology,Hepatology, Coloproctology. - 2002. - # 6. - S. 11-16. [Nikitin I.G.Lechenie hronicheskogo gepatita S: vchera, segodnja, zavtra.Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii.– 2002. - # 6. – S. 11-16.] In Russian
  • [7] Podymova SD. Liver disease: a guide. - 4th ed. Rev. and add.- Moscow: JSC „Publishing House“ Medicine“, 2005. - 768.[Podymova S.D. Bolezni pecheni: rukovodstvo. - 4-e izd.,pererab. i dop. - M.: OAO «Izdatel‘stvo «Medicina», 2005. -768 s.] In Russian
  • [8] Fedorchenko SV. Chronic HCV –infection. Monograph. - K.: TNI„Medicine“, 2010. - 272. [Fedorchenko S.V. Hronicheskaja HCV-infekcija: monografija. – K.: VSI «Medicina», 2010. – 272 s.] InRussian
  • [9] Kharchenko NV. Treatment of patients with chronic hepatitis C.Modern gastroenterology gepatology. -2000. - # 2. - S. 60-63.[Harchenko N.V. Lechenie bol‘nyh hronicheskim gepatitom S.Suchasna gastroenterologіja і gepatologіja. – 2000. - # 2. – S.60-63.] In Russian
  • [10] Affonso de Araujo FS, Courtouke C, Barone AA. Hepatitis C:shorter and better? Brasil J Inf Dis 2007; 11: 118-124
  • [11] Andriulli A, Mangia A, Iacobellis A, et al. Meta-analisis: the outcome of antiviral therapy in HCV genotype 2 and 3 pa¬tientswith chronic hepatitis. Aliment Pharmacol Ther 2008; 28:397-404[Crossref]
  • [12] Hadziyannis S, Cheinquer H, Morgan T, et al. Prospectiveevaluation of early virologic response associated withpeginterferon alfa-2a (PEGASIS) plus ribavirin therapy from aphase III, randomized, double-blind study examinity the effectof treatment duration and ribavirin dose. American Associationfor the study of Liver disease, 52nd Annual Meeting, November9-13th 2001, Dallas, USA
  • [13] Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis,management and treatment of hepatitis C: an up date.Hepatology 2009; 49: 1336-1374
  • [14] Mangia A, Minerva N, Bacca D, et al. Individualized treat¬mentduration for hepatitis C genotype 1 patients: randomizedcontrolled trial. Hepatology 2007; 47: 43-50[Crossref]
  • [15] Poynard T, Mc Hutchinson JG, Goodman Z, et al. Isan «a lacarte» combination interferon alfa-2b plus ribavirin regimenpossible for the first line treatment in patients with chronichepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31:211-218[Crossref]
  • [16] Wong JB, Mc Quillan GM, Mc Hutchinson JG, et al. Esti¬matingfuture hepatitis C morbidity, mortality and cots in the UnitedStates. Am J Public Health 2000; 90: 1562-1569
  • [17] Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T,Bielawski K. The role of iron overload and HFE gene mutationsin the era of pegylated interferon and ribavirin treatment ofchronic hepatitis C. Med Sci Monit 2010; 16(3):CR137-143
  • [18] Pawlowska M, Pilarczyk M, Halota W. Virologic response totreatment with Pegylated Interferon alfa-2b and Ribavirinfor chronic hepatitis C in children. Med Sci Monit 2010;16(12):CR616-621
  • [19] Dragomiretskaya N., Shevchenko N., Izha G., ZabolotnayaI., Kalinichenko N., & Zukow, W. Application of natural andphysical factors is in treatment of patients with chronic viralhepatitis S - ground of the use. Journal of Health Sciences.2013; 3(4): 153-163
  • [20] Dragomiretskaya N., Zabolotnaya I., Izha A., Shevchenko N., &Kalinichenko N. Results and prospects of further developmentof early rehabilitation and recovery treatment health patientswith gastroenterological profile in Ukraine (native studies).2012; 2(6): 42-54
  • [21] Dragomiretska N.V., Izha G.M., Zabolotna I.B., KalinichenkoM.V., Shevchenko N.O. Clinical experience of complexapplication of antiviral therapy, natural and preformed physicalfactors in patients with chronic hepatitis C. Gastroenterologia.2013; 47(1):. 1:60-64. Actual problems of transport medicine.2012; 4(30):117-123
  • [22] Dragomiretskaya N.V., Fedirko A.M. Irritable bowel syndrome:an opportunity for new approaches of treatment. Medicalrehabilitation, curortology, physiotherapy. 2011; 1(65):31-35
  • [23] Dragomiretskaya N.V., Zabolotnaya I.B., Malykhina T.I., IzhaA.N., Shevchenko N.A., Kalinichenko N.V. Viral hepatitis:standard therapy and usage of natural factors. Sovremennayagastroenterologia. 2011; 6 (62):92-98
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_1515_med-2015-0032
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.